(Q38004740)

26 August 2017

title

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia (English)

1 reference

26 August 2017

0 references

angiogenesis inhibitor

1 reference

Annamaria Rapisarda

1

1 reference

26 August 2017

Giovanni Melillo

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

24 April 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

7

1 reference

26 August 2017

page(s)

378-390

1 reference

Is angiogenesis an organizing principle in biology and medicine?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Clinical translation of angiogenesis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

VEGF-targeted therapy: mechanisms of anti-tumour activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia, HIF1 and glucose metabolism in the solid tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia signalling in cancer and approaches to enforce tumour regression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia--a key regulatory factor in tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-inducible factors and the response to hypoxic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-inducible factors in stem cells and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Regulation of metabolism by hypoxia-inducible factor 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Regulation of angiogenesis by hypoxia-inducible factor 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

EMT: a new vision of hypoxia promoting cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxic tumors and their effect on immune cells and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Development of HIF-1 inhibitors for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeting hypoxia in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Modes of resistance to anti-angiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Inhibiting hypoxia-inducible factor 1 for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hypoxia signalling through mTOR and the unfolded protein response in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Regulation of autophagy through multiple independent hypoxic signaling pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeting hypoxic cells through the DNA damage response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Development of a cell-based reporter assay for screening of inhibitors of hypoxia-inducible factor 2-induced gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

HIF-1: upstream and downstream of cancer metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

The interplay between MYC and HIF in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Glycolytic enzyme inhibitors in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeting MET in cancer: rationale and progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

CXCL12 (SDF-1)/CXCR4 pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

XBP1 is essential for survival under hypoxic conditions and is required for tumor growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Regulation of autophagy by ATF4 in response to severe hypoxia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Oxygen sensing and the DNA-damage response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

DNA repair pathways as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Molecular imaging of hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Molecular imaging of hypoxia with radiolabelled agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Avastin-Tarceva combination fails in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Human cancers converge at the HIF-2alpha oncogenic axis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Normalization of the vasculature for treatment of cancer and other diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Vascular normalization: a real benefit?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.64

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

31 March 2020

1 reference

12 December 2020

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

1 reference

12 December 2020

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality

1 reference

12 December 2020

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

12 December 2020

Metabolic microenvironment of tumor cells: a key factor in malignant progression

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells

1 reference

12 December 2020

Antiangiogenic therapy for cancer: current and emerging concepts

1 reference

12 December 2020

Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma

1 reference

12 December 2020

Glucose deprivation-induced metabolic oxidative stress and cancer therapy

1 reference

12 December 2020

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

1 reference

12 December 2020

10.1038/NRCLINONC.2012.64

Identifiers

DOI

1 reference

26 August 2017

1 reference